Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of ANF Rho in Chronic Neutropenia
2016-004539-18Phase 2Active
- Sponsor
- Prolong Pharmaceuticals
- Start
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegfilgrastim in neutropenia, sponsored by Prolong Pharmaceuticals. Started Jul 2017; status: active.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on 2016-004539-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004539-18.